These excerpts taken from the TPTX 8-K filed Oct 5, 2009.
Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statement: that Dr. Keltners appointment to the Raptor board will create value for our drug product candidate programs; that Raptors board and Raptor will be able to grow the company and increase stockholder value; that managements record of research, development and commercialization will serve as a strong foundation for Raptors clinical trials and other development activities; that DR Cysteamine will receive marketing approval; and that any of Raptors drug product programs will be successful. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Raptors actual results to be materially different from these forward-looking statements. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in Raptors filings from time to time with the Securities and Exchange Commission (the SEC), which Raptor strongly urges you to read and consider, including the joint proxy statement/prospectus on Form S-4 filed with the SEC on August 19, 2009; Raptors annual report on Form 10-K filed with the SEC on March 27, 2009; Raptors quarterly report on Form 10-Q filed with the SEC on August 11, 2009; Raptors wholly-owned subsidiarys, Raptor Pharmaceuticals Corp. (RPC) Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; RPCs annual report on Form 10-K filed with the SEC on October 30, 2008, as amended by that Form 10-K/A filed with the SEC on December 23, 2008; and RPCs quarterly report on Form 10-Q filed with the SEC on July 15, 2009, all of which are available free of charge on the SECs web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptors reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.
# # #